NGD-4715
NGD-4715 is a drug that was developed by Neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH 1 .
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
NGD-4715 is a drug that was developed by Neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH 1 . In animal models, it has anxiolytic, antidepressant, and anorectic effects, and it has successfully passed Phase I of clinical trials in humans.
Neurogen was acquired by Ligand Pharmaceuticals in August, 2009, and NGD-4715 was not listed among its key assets. All four laboratories were closed and sold, and no employees were retained. The structure of NGD-4715 is often confused with, for example 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372023821 under CC BY-SA 4.0; modifications have been made.